Clinical efficacy of azithromycin in lower respiratory tract infections. 1993

G Morandini, and M Perduca, and G Zannini, and M P Foschino, and G Miragliotta, and N S Carnimeo
Pneumology Division, Ospedale Maggiore, USSL 25, Verona, Italy.

A total of 51 patients with acute exacerbation of chronic bronchitis and pneumonia were enrolled: 27 treated with azithromycin (500 mg once a day for 3 days), and 24 with roxithromycin (150 mg every 12 hours for 7 days). The two regimens were equally effective, with clinical cure in 80% and 72% of patients respectively. Bacteriological eradication on day 19-23 was obtained in 7/11 cases (64%) and in 6/13 cases (46%) in the two groups, respectively. No side effects occurred in patients treated with azithromycin, while they occurred in the roxithromycin group (2 vomiting and 1 gastritis). Clinical and bacteriological efficacy, excellent tolerability, simplified dosage (single daily dose) and short-course (3 days) therapeutic regimen make azithromycin, in our experience, efficacious for the treatment of acute exacerbation of chronic bronchitis and community-acquired pneumonia.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001991 Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI. Bronchitides
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G Morandini, and M Perduca, and G Zannini, and M P Foschino, and G Miragliotta, and N S Carnimeo
January 1992, Scandinavian journal of infectious diseases. Supplementum,
G Morandini, and M Perduca, and G Zannini, and M P Foschino, and G Miragliotta, and N S Carnimeo
October 2005, Expert opinion on pharmacotherapy,
G Morandini, and M Perduca, and G Zannini, and M P Foschino, and G Miragliotta, and N S Carnimeo
March 2015, The Cochrane database of systematic reviews,
G Morandini, and M Perduca, and G Zannini, and M P Foschino, and G Miragliotta, and N S Carnimeo
January 2008, The Cochrane database of systematic reviews,
G Morandini, and M Perduca, and G Zannini, and M P Foschino, and G Miragliotta, and N S Carnimeo
October 2004, The Cochrane database of systematic reviews,
G Morandini, and M Perduca, and G Zannini, and M P Foschino, and G Miragliotta, and N S Carnimeo
September 1996, Indian journal of medical sciences,
G Morandini, and M Perduca, and G Zannini, and M P Foschino, and G Miragliotta, and N S Carnimeo
January 1989, Scandinavian journal of infectious diseases. Supplementum,
G Morandini, and M Perduca, and G Zannini, and M P Foschino, and G Miragliotta, and N S Carnimeo
January 2007, International journal of nanomedicine,
G Morandini, and M Perduca, and G Zannini, and M P Foschino, and G Miragliotta, and N S Carnimeo
June 1995, Minerva pediatrica,
G Morandini, and M Perduca, and G Zannini, and M P Foschino, and G Miragliotta, and N S Carnimeo
September 1991, The American journal of medicine,
Copied contents to your clipboard!